ID

35129

Description

GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations; ODM derived from: https://clinicaltrials.gov/show/NCT02047903

Link

https://clinicaltrials.gov/show/NCT02047903

Keywords

  1. 2/19/19 2/19/19 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

February 19, 2019

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Carcinoma, Non-Small-Cell Lung NCT02047903

Eligibility Carcinoma, Non-Small-Cell Lung NCT02047903

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
egfr- tyrosine kinase inhibitor (tki) naive patients with histologically confirmed locally advanced or metastatic nsclc with activating egfr-mutations
Description

EGFR tyrosine kinase inhibitor Absent | Non-Small Cell Lung Carcinoma Advanced Locally | Non-small cell lung cancer metastatic | EGFR Activating Mutation

Data type

boolean

Alias
UMLS CUI [1,1]
C1443775
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C0007131
UMLS CUI [2,2]
C0205179
UMLS CUI [2,3]
C1517927
UMLS CUI [3]
C0278987
UMLS CUI [4]
C2984891
age >= 18 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
patients for whom the treating physician has decided to initiate treatment with giotrif
Description

Therapeutic procedure Initiation | Afatinib

Data type

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1704686
UMLS CUI [2]
C2987648
written informed consent prior inclusion
Description

Informed Consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
contraindication for afatinib according to the summary of product characteristics
Description

Medical contraindication Afatinib

Data type

boolean

Alias
UMLS CUI [1,1]
C1301624
UMLS CUI [1,2]
C2987648
participation in another clinical study until 30 days after end of treatment
Description

Study Subject Participation Status

Data type

boolean

Alias
UMLS CUI [1]
C2348568
prior systemic chemotherapy (neo-/adjuvant therapy is permitted if at least 12 months has elapsed prior to disease progression)
Description

Systemic Chemotherapy

Data type

boolean

Alias
UMLS CUI [1]
C1883256
previous treatment with an egfr-tyrosine kinase inhibitor
Description

EGFR tyrosine kinase inhibitor Previous

Data type

boolean

Alias
UMLS CUI [1,1]
C1443775
UMLS CUI [1,2]
C0205156
patients not willing or not able to fill in quality of life questionnaires
Description

Quality of life Questionnaires Completion Unwilling | Quality of life Questionnaires Completion Unable

Data type

boolean

Alias
UMLS CUI [1,1]
C0034380
UMLS CUI [1,2]
C0034394
UMLS CUI [1,3]
C0205197
UMLS CUI [1,4]
C0558080
UMLS CUI [2,1]
C0034380
UMLS CUI [2,2]
C0034394
UMLS CUI [2,3]
C0205197
UMLS CUI [2,4]
C1299582
patients with missing or impaired legal capacity
Description

Legal capacity Missing | Legal capacity Impaired

Data type

boolean

Alias
UMLS CUI [1,1]
C0683673
UMLS CUI [1,2]
C1705492
UMLS CUI [2,1]
C0683673
UMLS CUI [2,2]
C0221099
pregnancy
Description

Pregnancy

Data type

boolean

Alias
UMLS CUI [1]
C0032961

Similar models

Eligibility Carcinoma, Non-Small-Cell Lung NCT02047903

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
EGFR tyrosine kinase inhibitor Absent | Non-Small Cell Lung Carcinoma Advanced Locally | Non-small cell lung cancer metastatic | EGFR Activating Mutation
Item
egfr- tyrosine kinase inhibitor (tki) naive patients with histologically confirmed locally advanced or metastatic nsclc with activating egfr-mutations
boolean
C1443775 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0007131 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
C1517927 (UMLS CUI [2,3])
C0278987 (UMLS CUI [3])
C2984891 (UMLS CUI [4])
Age
Item
age >= 18 years
boolean
C0001779 (UMLS CUI [1])
Therapeutic procedure Initiation | Afatinib
Item
patients for whom the treating physician has decided to initiate treatment with giotrif
boolean
C0087111 (UMLS CUI [1,1])
C1704686 (UMLS CUI [1,2])
C2987648 (UMLS CUI [2])
Informed Consent
Item
written informed consent prior inclusion
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Medical contraindication Afatinib
Item
contraindication for afatinib according to the summary of product characteristics
boolean
C1301624 (UMLS CUI [1,1])
C2987648 (UMLS CUI [1,2])
Study Subject Participation Status
Item
participation in another clinical study until 30 days after end of treatment
boolean
C2348568 (UMLS CUI [1])
Systemic Chemotherapy
Item
prior systemic chemotherapy (neo-/adjuvant therapy is permitted if at least 12 months has elapsed prior to disease progression)
boolean
C1883256 (UMLS CUI [1])
EGFR tyrosine kinase inhibitor Previous
Item
previous treatment with an egfr-tyrosine kinase inhibitor
boolean
C1443775 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
Quality of life Questionnaires Completion Unwilling | Quality of life Questionnaires Completion Unable
Item
patients not willing or not able to fill in quality of life questionnaires
boolean
C0034380 (UMLS CUI [1,1])
C0034394 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
C0558080 (UMLS CUI [1,4])
C0034380 (UMLS CUI [2,1])
C0034394 (UMLS CUI [2,2])
C0205197 (UMLS CUI [2,3])
C1299582 (UMLS CUI [2,4])
Legal capacity Missing | Legal capacity Impaired
Item
patients with missing or impaired legal capacity
boolean
C0683673 (UMLS CUI [1,1])
C1705492 (UMLS CUI [1,2])
C0683673 (UMLS CUI [2,1])
C0221099 (UMLS CUI [2,2])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial